NKMAX CO., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 07:34 am
Share
NKMAX CO., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was KRW 3,825.57 million compared to KRW 12,078.44 million a year ago. Basic loss per share from continuing operations was KRW 116 compared to KRW 361 a year ago. Diluted loss per share from continuing operations was KRW 116 compared to KRW 361 a year ago.
For the nine months, net loss was KRW 33,342.25 million compared to KRW 33,885.93 million a year ago. Basic loss per share from continuing operations was KRW 969 compared to KRW 1,055 a year ago. Diluted loss per share from continuing operations was KRW 969 compared to KRW 1,055 a year ago.
NKMAX Co., Ltd., formerly ATGen, is a Korea-based company principally engaged in the research, development, manufacturing and supply of biological products. The Company is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The Company distributes its products within domestic market and to overseas markets.
NKMAX CO., LTD. 
